These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24552817)

  • 1. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.
    Kim M; Chen X; Chin LJ; Paranjape T; Speed WC; Kidd KK; Zhao H; Weidhaas JB; Slack FJ
    Cell Cycle; 2014; 13(6):1030-40. PubMed ID: 24552817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.
    Chin LJ; Ratner E; Leng S; Zhai R; Nallur S; Babar I; Muller RU; Straka E; Su L; Burki EA; Crowell RE; Patel R; Kulkarni T; Homer R; Zelterman D; Kidd KK; Zhu Y; Christiani DC; Belinsky SA; Slack FJ; Weidhaas JB
    Cancer Res; 2008 Oct; 68(20):8535-40. PubMed ID: 18922928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
    Pharoah PD; Palmieri RT; Ramus SJ; Gayther SA; Andrulis IL; Anton-Culver H; Antonenkova N; Antoniou AC; Goldgar D; ; Beattie MS; Beckmann MW; Birrer MJ; Bogdanova N; Bolton KL; Brewster W; Brooks-Wilson A; Brown R; Butzow R; Caldes T; Caligo MA; Campbell I; Chang-Claude J; Chen YA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Despierre E; Doherty JA; Dörk T; Dürst M; Eccles DM; Ekici AB; Easton D; ; Fasching PA; de Fazio A; Fenstermacher DA; Flanagan JM; Fridley BL; Friedman E; Gao B; Sinilnikova O; ; Gentry-Maharaj A; Godwin AK; Goode EL; Goodman MT; Gross J; Hansen TV; Harnett P; Rookus M; ; Heikkinen T; Hein R; Høgdall C; Høgdall E; Iversen ES; Jakubowska A; Johnatty SE; Karlan BY; Kauff ND; Kaye SB; Chenevix-Trench G; ; Kelemen LE; Kiemeney LA; Kjaer SK; Lambrechts D; Lapolla JP; Lázaro C; Le ND; Leminen A; Leunen K; Levine DA; Lu Y; Lundvall L; Macgregor S; Marees T; Massuger LF; McLaughlin JR; Menon U; Montagna M; Moysich KB; Narod SA; Nathanson KL; Nedergaard L; Ness RB; Nevanlinna H; Nickels S; Osorio A; Paul J; Pearce CL; Phelan CM; Pike MC; Radice P; Rossing MA; Schildkraut JM; Sellers TA; Singer CF; Song H; Stram DO; Sutphen R; Lindblom A; ; Terry KL; Tsai YY; van Altena AM; Vergote I; Vierkant RA; Vitonis AF; Walsh C; Wang-Gohrke S; Wappenschmidt B; Wu AH; Ziogas A; Berchuck A; Risch HA;
    Clin Cancer Res; 2011 Jun; 17(11):3742-50. PubMed ID: 21385923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.
    Nelson HH; Christensen BC; Plaza SL; Wiencke JK; Marsit CJ; Kelsey KT
    Lung Cancer; 2010 Jul; 69(1):51-3. PubMed ID: 19854534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
    Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
    Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD.
    Hu H; Zhang L; Teng G; Wu Y; Chen Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1641-9. PubMed ID: 26316738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.
    Li ZH; Pan XM; Han BW; Guo XM; Zhang Z; Jia J; Gao LB
    Tumour Biol; 2013 Oct; 34(5):3159-63. PubMed ID: 23729275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells.
    Nakano H; Yamada Y; Miyazawa T; Yoshida T
    Int J Oncol; 2013 Jun; 42(6):1875-82. PubMed ID: 23588298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
    Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
    Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.
    Crowley EH; Arena S; Lamba S; Di Nicolantonio F; Bardelli A
    Hum Mutat; 2014 Feb; 35(2):208-14. PubMed ID: 24282149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
    Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
    Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
    Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
    Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer.
    Jin H; Liang Y; Wang X; Zhu J; Sun R; Chen P; Nie X; Gao L; Zhang L
    Med Oncol; 2014 Oct; 31(10):221. PubMed ID: 25201577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.
    Nodin B; Zendehrokh N; Sundström M; Jirström K
    Diagn Pathol; 2013 Jun; 8():106. PubMed ID: 23800114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.
    Hollestelle A; Pelletier C; Hooning M; Crepin E; Schutte M; Look M; Collee JM; Nieuwlaat A; Dorssers LC; Seynaeve C; Aulchenko YS; Martens JW; van den Ouweland AM; Weidhaas JB
    Breast Cancer Res Treat; 2011 Jul; 128(1):79-84. PubMed ID: 20676756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma.
    Pan XM; Jia J; Guo XM; Li ZH; Zhang Z; Qin HJ; Xu GH; Gao LB
    Fam Cancer; 2014 Mar; 13(1):93-7. PubMed ID: 23996697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
    De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H
    Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
    Paranjape T; Heneghan H; Lindner R; Keane FK; Hoffman A; Hollestelle A; Dorairaj J; Geyda K; Pelletier C; Nallur S; Martens JW; Hooning MJ; Kerin M; Zelterman D; Zhu Y; Tuck D; Harris L; Miller N; Slack F; Weidhaas J
    Lancet Oncol; 2011 Apr; 12(4):377-86. PubMed ID: 21435948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.